Search Advanced

AIMS Allergy and Immunology

2024, Volume 8, Issue 4: 324-332. doi: 10.3934/Allergy.2024020
Previous Article Next Article
Case report Special Issues

Challenges and management of bleeding in Kawasaki disease with aspirin treatment

  • 1.
    Children's Hospital, Shaanxi Provincial People's Hospital of Xian, Jiaotong Univeristy, Xian, China
  • 2.
    Department of Pediatrics, the First Affiliated Hospital of Yangtze University, Jingzhou, China
  • 3.
    Janaki Med college, Janakpur, Nepal
  • 4.
    Xian Medical College, Xian, China
  • 5.
    Taipei Medical University Shuanghe Hospital, Taiwan, China
  • 6.
    Department of Nursing, City College, Xi'an Jiaotong University, Xian, China
  • Received: 28 October 2024 Revised: 29 November 2024 Accepted: 11 December 2024 Published: 13 December 2024

  • The clinical management of Kawasaki disease (KD) presents challenges, particularly concerning the use of aspirin, which is a common treatment that can lead to systemic hemorrhage. This editorial explores the clinical characteristics, prognosis, and dosage considerations of aspirin-induced bleeding in KD. Through a review of five pediatric cases at Shaanxi Provincial People's Hospital, we highlight the need for careful aspirin dosing and vigilant monitoring to mitigate bleeding risks while maintaining the therapeutic efficacy. The aspirin dosage ranged from 40 mg–100 mg/kg/d, depending on patient condition. The average recovery time for patients was 10 days, with most patients showed significant improvements within 2 weeks. An enhanced awareness and tailored treatment strategies are critical to improve the outcomes of KD patients.

    Citation: Fuyong Jiao, Yan Pan, JAY N SHAH, Jiale Wang, Kaisheng Xie, Zhilong Mu, Qing Wei. Challenges and management of bleeding in Kawasaki disease with aspirin treatment[J]. AIMS Allergy and Immunology, 2024, 8(4): 324-332. doi: 10.3934/Allergy.2024020

    Related Papers:

  • The clinical management of Kawasaki disease (KD) presents challenges, particularly concerning the use of aspirin, which is a common treatment that can lead to systemic hemorrhage. This editorial explores the clinical characteristics, prognosis, and dosage considerations of aspirin-induced bleeding in KD. Through a review of five pediatric cases at Shaanxi Provincial People's Hospital, we highlight the need for careful aspirin dosing and vigilant monitoring to mitigate bleeding risks while maintaining the therapeutic efficacy. The aspirin dosage ranged from 40 mg–100 mg/kg/d, depending on patient condition. The average recovery time for patients was 10 days, with most patients showed significant improvements within 2 weeks. An enhanced awareness and tailored treatment strategies are critical to improve the outcomes of KD patients.



    加载中

    Acknowledgments


    This work was supported by Hubei Pediatric Alliance Medical Research Project (HPAMRP202117).

    Conflicts of interest


    Fuyong Jiao is an Guest editorial board member for AIMS Allergy and Immunology and was not involved in the editorial review or the decision to publish this article. All authors declare that there are no competing interests.

    Author contributions


    Fuyong Jiao: Data acquisition, data analysis, manuscript writing. Yan Pan: Data acquisition, pathological analysis. JAY N SHAH: Data acquisition, pathological analysis. Jiale Wang: Data analysis, manuscript revision. Kaisheng Xie, Zhilong Mu, Qing Wei: Conceptual design, manuscript writing, manuscript revision.

    Ethics statement


    In this study, we will adhere to ethical principles by ensuring that all participants provide informed consent, protecting their privacy and data security, and carefully addressing any potential conflicts of interest to maintain the integrity and fairness of the research.

    Patient informed consent


    In this study, patient informed consent will be obtained prior to participation, ensuring that participants are fully aware of the study's purpose, procedures, risks, and benefits.

    [1] Kawasaki T, Kosaki F, Okawa S, et al. (1974) A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 54: 271-276. https://doi.org/10.1542/peds.54.3.271
    [2] Wang CL, Wu YT, Liu CA, et al. (2005) Kawasaki disease: Infection, immunity and genetics. Pediatr Infect Dis J 24: 998-1004. https://doi.org/10.1097/01.inf.0000183786.70519.fa
    [3] Burns JC, Glode MP (2004) Kawasaki syndrome. Lancet 364: 533-544. https://doi.org/10.1016/S0140-6736(04)16814-1
    [4] Liang CD, Kuo HC, Yang KD, et al. (2009) Coronary artery fistula associated with Kawasaki disease. Am Heart J 157: 584-588. https://doi.org/10.1016/j.ahj.2008.11.020
    [5] Newburger JW, Takahashi M, Burns JC, et al. (1986) The treatment of Kawasaki syndrome with intravenous gamma globulin. New Engl J Med 315: 341-347. https://doi.org/10.1056/NEJM198608073150601
    [6] Hsieh KS, Weng KP, Lin CC, et al. (2004) Treatment of acute Kawasaki disease: Aspirin's role in the febrile stage revisited. Pediatrics 114: e689-e693. https://doi.org/10.1542/peds.2004-1037
    [7] Jiao F, Pan Y, Du Z, et al. (2024) Guideline for the diagnosis and treatment of incomplete Kawasaki disease in children in China. BMC Pediatr 24: 477. https://doi.org/10.1186/s12887-024-04961-2
    [8] Takahashi K, Oharaseki T, Yokouchi Y (2018) Histopathological aspects of cardiovascular lesions in Kawasaki disease. Int J Rheum Dis 21: 31-35. https://doi.org/10.1111/1756-185X.13207
    [9] Burns JC, Glode MP, Clarke SH, et al. (1984) Coagulopathy and platelet activation in Kawasaki syndrome: Identification of patients at high risk for development of coronary artery aneurysms. J Pediatr 105: 206-211.
    [10] Lee G, Lee SE, Hong YM, et al. (2013) Is high-dose aspirin necessary in the acute phase of Kawasaki disease?. Korean Circ J 43: 182-186. https://doi.org/10.4070/kcj.2013.43.3.182
    [11] Durongpisitkul K, Gururaj VJ, Park JM, et al. (1995) The prevention of coronary artery aneurysm in Kawasaki disease: A meta-analysis on aspirin and immunoglobulin treatment efficacy. Pediatrics 96: 1057-1061. https://doi.org/10.1542/peds.96.6.1057
    [12] Saulsbury FT (2002) Comparison of high-dose and low-dose aspirin plus intravenous immunoglobulin in the treatment of Kawasaki syndrome. Clin Pediatr 41: 597-601. https://doi.org/10.1177/000992280204100807
    [13] Yeomans ND, Lanas AI, Talley NJ, et al. (2005) Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 22: 795-801. https://doi.org/10.1111/j.1365-2036.2005.02649.x
    [14] Campbell CL, Smyth S, Montalescot G, et al. (2007) Aspirin dose for the prevention of cardiovascular disease: A systematic review. JAMA 297: 2018-2024. https://doi.org/10.1001/jama.297.18.2018
    [15] Roth GJ, Stanford N, Majerus P (1975) Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci 72: 3073-3076. https://doi.org/10.1073/pnas.72.8.3073
    [16] Moncada S, Gryglewski RJ, Bunting S, et al. (1976) A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X), which prevents platelet aggregation. Prostaglandins 12: 715-737. https://doi.org/10.1016/0090-6980(76)90048-4
    [17] Cheng Y, Wang M, Yu Y, et al. (2006) Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest 116: 1391-1399. https://doi.org/10.1172/JCI27540
    [18] Vane JR, Bakhle YS, Botting RM (1998) Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38: 97-120. https://doi.org/10.1146/annurev.pharmtox.38.1.97
    [19] Matsubara T, Mason W, Kashani IA, et al. (1996) Gastrointestinal hemorrhage complicating aspirin therapy in acute Kawasaki disease. J Pediatr 128: 701-703. https://doi.org/10.1016/S0022-3476(96)80140-5
    [20] Kuo HC, Lo MH, Hsieh KS, et al. (2015) High-dose aspirin is associated with anemia and does not confer benefit to disease outcomes in Kawasaki disease. PLoS One 10: e0144603. https://doi.org/10.1371/journal.pone.0144603
    [21] Lee JH, Hung HY, Huang FY (1992) Kawasaki disease with Reye syndrome: Report of one case. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi 33: 67-71.
  • Reader Comments
  • © 2024 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索
AIMS Allergy and Immunology
0.9

Metrics

Article views(384) PDF downloads(23) Cited by(0)

Preview PDF
Download XML
Export Citation
Article outline

Figures and Tables

Tables(1)

Other Articles By Authors

Related pages

Tools

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog